NCT04826172

Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)

A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 58 (actual)
• Sponsor: Imbria Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 35 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and tolerability of IMB-1018972 in subjects with obstructive CAD and inducible ischemia.

Conditions

• Ischemia
• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	IMB-1018972	Modified release (MR) oral tablet
DRUG	Placebo	Matching oral tablet

Timeline

• Start date: 2021-04-23
• Primary completion: 2023-09-21
• Completion: 2023-09-21
• First posted: 2021-04-01
• Last updated: 2024-04-23

Locations

3 sites across 3 countries: Denmark, Finland, Sweden

Regulatory

• FDA-regulated drug study